WO2023023150A3 - Methods and compositions related to neutralizing antibodies against human coronavirus - Google Patents

Methods and compositions related to neutralizing antibodies against human coronavirus Download PDF

Info

Publication number
WO2023023150A3
WO2023023150A3 PCT/US2022/040592 US2022040592W WO2023023150A3 WO 2023023150 A3 WO2023023150 A3 WO 2023023150A3 US 2022040592 W US2022040592 W US 2022040592W WO 2023023150 A3 WO2023023150 A3 WO 2023023150A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
antibodies against
neutralizing antibodies
against human
antigen
Prior art date
Application number
PCT/US2022/040592
Other languages
French (fr)
Other versions
WO2023023150A2 (en
Inventor
Liang SCHWEIZER
Francisco Adrian
Matthieu DELINCE
Roshan Moti KUMAR
Qian Zhang
Original Assignee
Hifibio (Hk) Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hifibio (Hk) Limited filed Critical Hifibio (Hk) Limited
Publication of WO2023023150A2 publication Critical patent/WO2023023150A2/en
Publication of WO2023023150A3 publication Critical patent/WO2023023150A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)

Abstract

The invention described herein provides neutralizing monoclonal recombinant antibodies or antigen-binding fragments against SARS-CoV-2 antigens (such as the S1 subunit of the S antigen) for use in treating human patients having COVID-19. Additionally the antibodies or antigen-binding fragments may be used for methods of screening, in particular, the combined droplet-based single cell screening with mass spectrometry.
PCT/US2022/040592 2021-08-18 2022-08-17 Methods and compositions related to neutralizing antibodies against human coronavirus WO2023023150A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163234296P 2021-08-18 2021-08-18
US63/234,296 2021-08-18

Publications (2)

Publication Number Publication Date
WO2023023150A2 WO2023023150A2 (en) 2023-02-23
WO2023023150A3 true WO2023023150A3 (en) 2023-08-31

Family

ID=85240995

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2022/040592 WO2023023150A2 (en) 2021-08-18 2022-08-17 Methods and compositions related to neutralizing antibodies against human coronavirus

Country Status (1)

Country Link
WO (1) WO2023023150A2 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040265960A1 (en) * 2003-03-14 2004-12-30 Wyeth Antibodies against human IL-21 receptor and uses therefor
US20050266423A1 (en) * 2000-01-25 2005-12-01 Nuvelo, Inc. Novel nucleic acids and polypeptides
US20140356385A1 (en) * 2011-12-23 2014-12-04 Innate Pharma Enzymatic conjugation of antibodies
US20180194809A1 (en) * 2015-06-17 2018-07-12 International Aids Vaccine Initiative Engineered outer domain (eod) of hiv gp120, mutants and use thereof
WO2019222275A2 (en) * 2018-05-14 2019-11-21 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using inducible fusion proteins

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050266423A1 (en) * 2000-01-25 2005-12-01 Nuvelo, Inc. Novel nucleic acids and polypeptides
US20040265960A1 (en) * 2003-03-14 2004-12-30 Wyeth Antibodies against human IL-21 receptor and uses therefor
US20140356385A1 (en) * 2011-12-23 2014-12-04 Innate Pharma Enzymatic conjugation of antibodies
US20180194809A1 (en) * 2015-06-17 2018-07-12 International Aids Vaccine Initiative Engineered outer domain (eod) of hiv gp120, mutants and use thereof
WO2019222275A2 (en) * 2018-05-14 2019-11-21 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using inducible fusion proteins

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE Genbank NCBI; . : "IGH c820_heavy_IGHV2-70_IGHD1-26_IGHJ3, partial [Homo sapiens]", XP093089475 *
JASON A. VANDER HEIDEN, ET AL.: "Dysregulation of B Cell Repertoire Formation in Myasthenia Gravis Patients Revealed through Deep Sequencing", THE JOURNAL OF IMMUNOLOGY, WILLIAMS & WILKINS CO., US, vol. 198, no. 4, 15 February 2017 (2017-02-15), US , pages 1460 - 1473, XP055636836, ISSN: 0022-1767, DOI: 10.4049/jimmunol.1601415 *

Also Published As

Publication number Publication date
WO2023023150A2 (en) 2023-02-23

Similar Documents

Publication Publication Date Title
PH12021550793A1 (en) Anti-SARS-CoV-2-Spike Glycoprotein Antibodies and Antigen-Binding Fragments
MX2021005708A (en) Anti-nkg2a antibodies and uses thereof.
UA92504C2 (en) Anti-myostatin monoclonal antibody
PE20071055A1 (en) ANTI MN ANTIBODIES
MX2017013113A (en) Anti-pacap antibodies and uses thereof.
MX2022007231A (en) Anti-mertk antibodies and methods of use thereof.
EA202192090A1 (en) ANTIGEN BINDING PROTEINS AGAINST IL2 RECEPTOR GAMMA CHAIN
WO2021207433A3 (en) Epitopes of sars-cov-2 neutralizing antibodies
WO2022081718A8 (en) Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
MX2021015156A (en) Anti-pcrv antibodies that bind pcrv, compositions comprising anti-pcrv antibodies, and methods of use thereof.
MX2022012628A (en) Anti-phf-tau antibodies and uses thereof.
MX2021006362A (en) Single domain antibodies against cll-1.
WO2022034524A3 (en) Antibodies against ilt2 and use thereof
WO2021087368A3 (en) Anti-cd45 antibodies and conjugates thereof
WO2022006555A3 (en) BISPECIFIC ANTIGEN BINDING PROTEINS TARGETING PD-L1 AND TGF-β AND METHODS OF USE
WO2021067633A3 (en) Kir3dl3 is an inhibitory receptor of the immune system and uses thereof
WO2022020234A3 (en) Immunoassay for sars-cov-2 neutralizing antibodies and materials therefor
WO2023023150A3 (en) Methods and compositions related to neutralizing antibodies against human coronavirus
MX2022000484A (en) Novel bssl antibodies.
WO2021257695A3 (en) Methods and compositions related to neutralizing antibodies against human coronavirus
WO2003059953A3 (en) Anti-idiotypic antibody inducing hiv-1 neutralizing antibodies
WO2022200291A3 (en) Human neutralizing antigen specific proteins for spike-rbd of sars-cov-2
WO2023122211A3 (en) Coronavirus antibodies and uses thereof
WO2005077412A3 (en) Compositions and methods of use of w-peptides
MX2022014455A (en) Stable anti-clever-1 antibody formulation.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22859102

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE